Advanced Medical Solutions Group Regulatory News (AMS)

For Release: 9 February 2011

("AMS" or "the Company")

Notice of Preliminary Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its preliminary results for the year ended 31 December 2010 on Tuesday 8 March 2011.

A briefing for analysts will be held at 9.30am on the day of the results at the offices of Tavistock Communications, 131 Finsbury Pavement, London EC2A 1NT

- ends -

For further enquiries:

Advanced Medical Solutions Group plc +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director

Tavistock Communications +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn / Lydia Eades

Investec Bank plc +44 (0) 20 7597 5970

Gary Clarence / Patrick Robb / Daniel Adams

Notes to Editors:

AMS' advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS' wound closure and sealants products are based on cyanoacrylate adhesive ("superglue") technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.